Safety first
The clinical trial of an Indian AIDS vaccine has been delayed because of the lack of safety data. The tests, being coordinated by the International Aids Vaccine Initiative (IAVI), were to be held in July. They have now been rescheduled for the end of 2004 or early 2005.
The phase-I trials were to be carried out at the Pune-based National AIDS Research Institute (NARI) under the Indian Council of Medical Research. IAVI will now have to provide more data on the studies conducted on animals to the Drug Controller General of India. Researchers from NARI have identified the genes used to make the vaccine. It is being provided by Therion Biologic Corporation, USA, which also carried out the toxicological studies.
Related Content
- 2023 state of the artisanal and small-scale mining sector
- South Africa economic update- safety first: the economic cost of crime in South Africa
- Progress on household drinking water, sanitation and hygiene 2000–2022: special focus on gender
- State food safety index: creating competitive environment for safe food across States/UTs 2022-2023
- Order of the National Green Tribunal regarding oil spill along the coast of Nagapattinam, Tamil Nadu, 28/03/2023
- Order of the National Green Tribunal regarding gas leak in an apparel factory at Atchutapuram in Anakapalli district, Andhra Pradesh, 18/01/2023